What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.”In the company’s words, NCT04752813 on ClinicalTrials.gov
- Tested for
- Glioblastoma, Glioblastoma Multiforme
- Main trialPhase 2
- “This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.”In the company’s words, NCT04752813 on ClinicalTrials.gov
- Other names
- API 31510 · Ubidecarenone · USP
Other drugs for Glioblastoma
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- LAM561Laminar Pharmaceuticals · Phase 2/3
- VebreltinibBeijing Pearl Biotechnology Limited Liability Company · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 25 Aug 2026 | A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | |
| Phase 2Completed | 11 Jun 2019 | BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients | |
| Phase 1/2Completed | Jan 2010 | Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026